MA58885B1 - Formes cristallines d'un composé pharmaceutique - Google Patents

Formes cristallines d'un composé pharmaceutique

Info

Publication number
MA58885B1
MA58885B1 MA58885A MA58885A MA58885B1 MA 58885 B1 MA58885 B1 MA 58885B1 MA 58885 A MA58885 A MA 58885A MA 58885 A MA58885 A MA 58885A MA 58885 B1 MA58885 B1 MA 58885B1
Authority
MA
Morocco
Prior art keywords
compound
crystalline forms
pharmaceutical compound
relates
crystalline form
Prior art date
Application number
MA58885A
Other languages
English (en)
French (fr)
Inventor
Robert Hett
Fritz Blatter
Jennifer Robin
Kyle Landskroner
Original Assignee
Azafaros B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azafaros B V filed Critical Azafaros B V
Publication of MA58885B1 publication Critical patent/MA58885B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA58885A 2020-10-02 2021-10-01 Formes cristallines d'un composé pharmaceutique MA58885B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20199934.9A EP3978474A1 (en) 2020-10-02 2020-10-02 Crystalline forms of a pharmaceutical compound
PCT/EP2021/077100 WO2022069709A1 (en) 2020-10-02 2021-10-01 Crystalline forms of a pharmaceutical compound

Publications (1)

Publication Number Publication Date
MA58885B1 true MA58885B1 (fr) 2023-11-30

Family

ID=72744696

Family Applications (1)

Application Number Title Priority Date Filing Date
MA58885A MA58885B1 (fr) 2020-10-02 2021-10-01 Formes cristallines d'un composé pharmaceutique

Country Status (19)

Country Link
US (2) US12116344B2 (cg-RX-API-DMAC10.html)
EP (3) EP3978474A1 (cg-RX-API-DMAC10.html)
JP (2) JP7809655B2 (cg-RX-API-DMAC10.html)
KR (2) KR20240056628A (cg-RX-API-DMAC10.html)
CN (1) CN116390910A (cg-RX-API-DMAC10.html)
AU (2) AU2021353055B2 (cg-RX-API-DMAC10.html)
BR (2) BR122022018214A2 (cg-RX-API-DMAC10.html)
CA (1) CA3193939C (cg-RX-API-DMAC10.html)
CL (1) CL2023000943A1 (cg-RX-API-DMAC10.html)
DK (1) DK4114826T3 (cg-RX-API-DMAC10.html)
ES (1) ES2964105T3 (cg-RX-API-DMAC10.html)
FI (1) FI4114826T3 (cg-RX-API-DMAC10.html)
IL (2) IL316634A (cg-RX-API-DMAC10.html)
MA (1) MA58885B1 (cg-RX-API-DMAC10.html)
MX (1) MX2023003618A (cg-RX-API-DMAC10.html)
PE (1) PE20240138A1 (cg-RX-API-DMAC10.html)
TW (1) TWI912383B (cg-RX-API-DMAC10.html)
WO (1) WO2022069709A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202310184B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978474A1 (en) * 2020-10-02 2022-04-06 Azafaros B.V. Crystalline forms of a pharmaceutical compound
IL314212A (en) * 2022-01-10 2024-09-01 Azafaros B V Treatment of GM2 gangliosidosis
EP4209215A1 (en) * 2022-01-10 2023-07-12 Azafaros B.V. Treatment of gm2 gangliosidosis
AU2025214578A1 (en) 2024-02-01 2026-08-13 Azafaros B.V. Treatment of gm1 gangliosidosis
EP4595964A1 (en) 2024-02-01 2025-08-06 Azafaros B.V. Treatment of gm1 gangliosidosis
EP4678174A1 (en) * 2024-07-11 2026-01-14 Azafaros B.V. Nizubaglustat for use in the treatment of lysosomal storage disorders
WO2026013261A1 (en) * 2024-07-11 2026-01-15 Azafaros B.V. Nizubaglustat for use in the treatment of lysosomal storage disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2895490T3 (es) 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
US20190195897A1 (en) * 2015-06-24 2019-06-27 Universiteit Leiden Glycosylated metabolites
EP3978474A1 (en) * 2020-10-02 2022-04-06 Azafaros B.V. Crystalline forms of a pharmaceutical compound

Also Published As

Publication number Publication date
WO2022069709A1 (en) 2022-04-07
JP7809655B2 (ja) 2026-02-02
AU2021353055B2 (en) 2022-10-06
TWI912383B (zh) 2026-01-21
TW202229236A (zh) 2022-08-01
EP3978474A1 (en) 2022-04-06
MX2023003618A (es) 2023-07-14
AU2022291486A1 (en) 2023-02-02
ES2964105T3 (es) 2024-04-04
FI4114826T3 (fi) 2023-11-21
IL301882B1 (en) 2024-12-01
EP4114826A1 (en) 2023-01-11
CL2023000943A1 (es) 2023-09-29
DK4114826T3 (da) 2023-11-13
PE20240138A1 (es) 2024-01-30
NZ798892A (en) 2023-09-29
IL301882A (en) 2023-06-01
CN116390910A (zh) 2023-07-04
KR20240056628A (ko) 2024-04-30
BR112022018020A2 (pt) 2023-04-18
JP2024054192A (ja) 2024-04-16
IL301882B2 (en) 2025-04-01
BR112022018020B1 (pt) 2023-12-26
CA3193939C (en) 2024-02-20
EP4295847A3 (en) 2024-02-28
US20230391724A1 (en) 2023-12-07
ZA202310184B (en) 2024-01-31
AU2021353055A1 (en) 2022-09-15
KR20230078798A (ko) 2023-06-02
US12116344B2 (en) 2024-10-15
AU2022291486B2 (en) 2024-07-25
US20250059137A1 (en) 2025-02-20
KR102659466B1 (ko) 2024-04-19
US20240287001A9 (en) 2024-08-29
JP2023524169A (ja) 2023-06-08
CA3193939A1 (en) 2022-04-07
IL316634A (en) 2024-12-01
EP4295847A2 (en) 2023-12-27
EP4114826B1 (en) 2023-08-23
BR122022018214A2 (pt) 2023-05-09

Similar Documents

Publication Publication Date Title
Chong et al. Antiviral treatment guidelines for Middle East respiratory syndrome
TN2009000059A1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
MA49235A (fr) Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
EP4295847A3 (en) Crystalline forms of a pharmaceutical compound
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
US20100120787A1 (en) Modification of amyloid-beta load in non-brain tissue
BR112021012654A2 (pt) Métodos de tratamento de infecções por tempestade de citocina, incluindo covid-19, através da inibição da interação ccr5/ccl5 (rantes) e composições para a prática da mesma
EP1841426A4 (en) ACTIVE TERTIARY CARBINAMINES WITH SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF ALZHEIMER DISEASE AS INHIBITORS OF BETA-SECRETASE
MA30335B1 (fr) Compositions antibiotiques a liberation modifiee et leur procede de production
BR0213138A (pt) Métodos de tratar ou prevenir mal de alzheimer e uma doença distinguida por depósito de beta-amilóide no cérebro, de tratar um paciente que tenha, ou de prevenir um paciente de contrair uma doença ou condição, de produzir um complexo de beta-secretase e de inibir a produção de placa beta-amilóide em um animal, composição e uso de um composto
DE112011105169T5 (de) Neue pharmazeutische Zusammensetzung mit geringen Nebenwirkungen enthaltend anti-Tuberkulose Arzneimittel
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
Yong et al. Primary selection into shift work and change of cardiovascular risk profile
BRPI0409151A (pt) uso de derivados de 10-hidróxi-10,11-diidrocarbamazepina para o tratamento de transtornos afetivos
MA56330B1 (fr) Composition pharmaceutique comprenant un composé de tétrahydropyrazolopyrimidinone
MA31204B1 (fr) Sels d'addition acides, hydrates et polymorphes d'ethylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phenyl) -4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylique et preparations comprenant ces formes
MA29950B1 (fr) Nouveau derive de la pleuromutiline et son utilisation
BR0211030A (pt) Derivado de pirrolidina oxadiazole, uso de um derivado de pirrolidina oxadiazole, composição farmacêutica contendo pelo menos um derivado de pirrolidina oxadiazole, método para preparação de um composto de pirrolidina oxadiazole
Pirapaharan et al. A mild inhibition of cathepsin K paradoxically stimulates the resorptive activity of osteoclasts in culture
MA66471B1 (fr) Formes cristallines de dérivés de quinazoline, leur préparation, leur composition et leur utilisation
MA24704A1 (fr) Formulations nouvelles de paroxetine et procede pour leur preparation
MA27690A1 (fr) Composition pharmaceutique androgene et procede pour le traitement de la depression.
EP0368994B1 (en) Benzothiazepines for the preparation of medicaments for the amelioration of epileptic seizures
Mori et al. Morphometric and microscopic evaluation of the effect of solution of acetazolamide as an intracanal therapeutic agent in late reimplanted rat teeth